Evonik Launches Next-Generation Liposomal Drug Manufacturing Equipment

Evonik Health Care, an integrated contract development and manufacturing organization (CDMO) that offers excipients, formulation technologies, and clinical and commercial manufacturing, is also offering a new version of its established LIPEX liposome extruder. The next-generation equipment, LIPEX Flow, will be available worldwide beginning in November, the company announced in an Oct. 15, 2021 press release. Evonik also uses the equipment in-house in its CDMO operations, the company says.

LIPEX Flow meets the market need for more efficient, next-generation high pressure extruders to produce drug products requiring conventional liposomal drug delivery, including drugs for oncology, vaccines, and other applications. Lipid-based particles, in particular conventional liposomes, provide a versatile and flexible drug delivery platform for several classes of APIs including small molecules, drug-lipid conjugates, proteins, and peptides, the company stated in the press release.

The company’s LIPEX extruders are used for size reduction of liposomal drug formulations to achieve a specified vesicle size in a reproducible and scalable process. The next-generation extruder’s patent-pending design maximizes the effective filter area, which results in lower extrusion pressures. The new extruder offers higher throughput, faster batch production times, and a broader operating range. It also supports the scale-up of processes from drug discovery through to good manufacturing practice at lab, pilot, intermediate, and commercial-scale volumes.

Source: Evonik